Published online 27 August 2009
Haematologica, Vol 94, Issue 10, 1362-1367 doi:10.3324/haematol.2009.009134
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Lucas, C. M.
Right arrow Articles by Clark, R. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucas, C. M.
Right arrow Articles by Clark, R. E.

Chronic Myeloid Leukemia

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Claire M. Lucas, Robert J. Harris, Athina Giannoudis, Andrea Davies, Katy Knight, Sarah J. Watmough, Lihui Wang, Richard E. Clark

Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK

Correspondence: Richard Clark, Department of Haematology, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK. E-mail:r.e.clark{at}liv.ac.uk.

Background: Chronic myeloid leukemia is characterized by a reciprocal translocation between chromosomes 9 and 22, creating the fusion gene BCR-ABL. The clinical significance of the type of BCR-ABL transcript in newly diagnosed patients in chronic phase treated with imatinib 400 mg from initial diagnosis remains unknown.

Design and Methods: We analyzed the clinical outcome of 78 newly diagnosed chronic phase patients, aged 16 or over, treated with imatinib 400 mg. Of these, 71 expressed either e13a2 or e14a2 transcripts. BCR-ABL transcripts were assayed by quantitative real-time polymerase chain reaction.

Results: After 12 months of treatment, 54% of the e14a2 patients had achieved a complete cytogenetic response, compared to 25% of the e13a2 patients (p=0.01). Kaplan-Meier analysis of the time to achieve complete cytogenetic response revealed that e14a2 patients had more rapid response rates, compared to e13a2 patients (p=0.006). e14a2 patients had a higher event-free survival rate in the first 12 months of treatment, although overall survival did not differ significantly between the patients with the two types of transcript. Human organic cation transporter protein 1 mRNA levels did not differ between the patients with the two types of transcript. The pre-treatment pCrKL/CrKL ratio (a surrogate marker of BCR-ABL tyrosine kinase activity) was higher in patients with e13a2 transcripts than in those with e14a2 (p=0.017).

Conclusions: Patients expressing the e14a2 transcript type have a higher rate and more rapid complete cytogenetic responses than e13a2-expressing patients, which may be due to higher BCR-ABL tyrosine kinase activity. Knowledge of the transcript type may yield additional prognostic information, although this requires testing on larger datasets.

Key words: chronic myeloid leukemia, BCR-ABL fusion transcript, imatinib.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Yuan, Z. Wang, C. Gao, W. Chen, Q. Huang, J.-K. Yee, R. Bhatia, and W. Chen
BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia
J. Biol. Chem., February 12, 2010; 285(7): 5085 - 5096.
[Abstract] [Full Text] [PDF]